Moderna
MRNA
$0.13 (-0.31%)
1D
1W
3M
1Y
5Y
ALL
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Finbold • 7 hours ago • MRNA
Wall Street's top 5 stocks with the biggest upside in 2025GlobeNewsWire • 12 hours ago • MRNA
mRNA Vaccines and Therapeutics Market Expected to Reach USD 253.83 Billion By 2034, With 16.7% CAGR From 2025 to 2034 | PMRZacks Investment Research • 3 days ago • MRNA
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?The Motley Fool • 6 days ago • MRNA
Is Moderna Stock a Buy?The Motley Fool • 6 days ago • MRNA
3 Stocks That Could Turn $1,000 into $5,000 by 2030Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.